Efficacy and Safety of Endostar® Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas

  • Zhang, Lu-Ping (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Liao, Xing-Yun (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Xu, Yan-Mei (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Yan, Lv-Jun (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Yan, Gui-Fang (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Wang, Xin-Xin (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Duan, Yu-Zhong (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Sun, Jian-Guo (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University)
  • Published : 2013.07.30


Background: Soft tissue sarcomas (STS) are a heterogeneous group of tumors, and approximately 40-50% of patients with STS develop metastatic disease. The median overall survival of those patients was 12 months and their 5-year survival rate was 8%. Therefore, study on more effective treatment, especially the targeting therapies, is urgently needed. Objective: To evaluate the efficacy and safety of Endostar$^{(R)}$ combined with chemotherapy in patients with advanced STS. Methods: A retrospective case-series study was conducted in Cancer Institute of PLA, Xinqiao Hospital. A total of 71 patients suffering from advanced STS (IIB - IV) were included, of whom 49 cases treated with chemotherapy alone were defined as the control group and the rest 22 cases treated with the traditional chemotherapy combined with Endostar$^{(R)}$ were defined as the test group. The short-term therapeutic effects including objective response rate (ORR), disease control rate (DCR) and safety were evaluated in the two groups. In the follow-up, progression-free survival (PFS) and overall survival (OS) were also observed. Results: In the test and control groups, the ORR was 18.2% and 12.2%, respectively (P=0.767), and the DCR was 86.4% and 61.2%, respectively (P=0.034). The median time to progression in the test and control groups was 120 days and 70 days with significant difference (P = 0.017), while the median overall survival was 452 days and 286 days without significant difference (P=0.503). The one-year survival rate in the test group and control group was 56.2% and 35.4%, respectively, while the two-year survival rate was 30.2% and 26.5%, respectively. No significant difference in the side effects was found between the two groups. Conclusions: Endostar$^{(R)}$ combined with chemotherapy resulted in a higher DCR and longer PFS in the patients with advanced STS, and the toxicity was tolerable.


  1. Olsson AK, Johansson I, Akerud H, et al (2004). The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Res, 64, 9012-17.
  2. Purohit S, Bhise R, Appachu S, et al (2011). Systemic therapy in soft tissue sarcomas: past, present and future. Indian J Surg Oncol, 2, 327-31.
  3. Reichardt P, Reichardt A, Pink D (2011). Molecular targeted therapy of gastrointestinal stromal tumors. Curr Cancer Drug Targets, 11, 688-97.
  4. Riedel RF (2012). Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. Cancer, 118, 1474-85.
  5. Sasaki T, Janne PA (2011). New strategies for treatment of ALK-rearranged non-small cell lung cancers. Clin Cancer Res, 17, 7213-18.
  6. Shukla NK, Deo SV (2011). Soft tissue sarcoma-review of experience at a tertiary care cancer centre. Indian J Surg Oncol, 2, 309-12.
  7. Tsukagoshi S (2010). [Introductory remarks of the 9th International Conference of the Asian Clinical Oncology Society (ACOS) Congress--Talk to the World Wide from Asia]. Gan To Kagaku Ryoho, 37, 2021-23.
  8. Vincenzi B, Napolitano A, D Onofrio L, et al (2011). Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. Expert Opin Investig Drugs, 20, 1685-705.
  9. Wang J, Sun Y, Liu Y, et al (2005). [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi, 8, 283-90.
  10. Blay JY, Le CA, Cassier PA, et al (2012). Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Discov Med, 13, 357-67.
  11. Brand TM, Iida M, Wheeler DL (2011). Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther, 11, 777-92.
  12. Cen L, Hsieh FC, Lin HJ, et al (2007). PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer, 97, 785-91.
  13. Cohen MH, Johnson JR, Chattopadhyay S, et al (2010). Approval summary: erlotinib maintenance therapy of advanced/ metastatic non-small cell lung cancer (NSCLC). Oncologist, 15, 1344-51.
  14. Cormier JN, Pollock RE (2004). Soft tissue sarcomas. CA Cancer J Clin, 54, 94-109.
  15. Folkman J (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol, 29, 15-8.
  16. Heudel P, Cassier P, Derbel O, et al (2012). Pazopanib for the treatment of soft-tissue sarcoma. Clin Pharmacol, 4, 65-70.
  17. Italiano A, Mathoulin-Pelissier S, Cesne AL, et al (2011). Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer, 117, 1049-54.
  18. Jia Y, Liu M, Huang W, et al (2012). Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathol Oncol Res, 18, 315-23.
  19. Jiang LP, Zou C, Yuan X, et al (2009). N-terminal modification increases the stability of the recombinant human endostatin in vitro. Biotechnol Appl Biochem, 54, 113-20.
  20. Judson I (2010). Targeted therapies in soft tissue sarcomas. Ann Oncol, 21, vii277-80.
  21. Kaya M, Wada T, Nagoya S, et al (2007). Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J Orthop Sci, 12, 562-7.
  22. Ke QH, Zhou SQ, Huang M, et al (2012). Early efficacy of Endostar combined with chemoradiotherapy for advanced cervical cancers. Asian Pac J Cancer Prev, 13, 923-26.
  23. Li Y, Huang XE, Yan PW, et al (2010). Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Asian Pac J Cancer Prev, 11, 1119-23.

Cited by

  1. Computed Tomography Manifestations of Histologic Subtypes of Retroperitoneal Liposarcoma vol.15, pp.15, 2014,
  2. Anti-Tumor Effect of a Novel Soluble Recombinant Human Endostatin: Administered as a Single Agent or in Combination with Chemotherapy Agents in Mouse Tumor Models vol.9, pp.9, 2014,
  3. New Therapeutic Schedule for Prostatic Cancer-3 Cells with ET-1 RNAi and Endostar vol.15, pp.23, 2015,
  4. Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors vol.97, pp.45, 2018,